Terms: = Germ cell tumor AND ZFHX3, ATBT, 463, ENSG00000140836, Q15911 AND Treatment
52 results:
1. Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.
Lu Y; Liao L; Du K; Mo J; Zou X; Liang J; Chen J; Tang W; Su L; Wu J; Zhang J; Tan Y
BMC Cancer; 2024 Jan; 24(1):133. PubMed ID: 38273249
[TBL] [Abstract] [Full Text] [Related]
2. Risk factors for cervical lymph node metastasis in the central or lateral cervical region in medullary thyroid carcinoma: a systematic review and meta-analysis.
Lin X; Huo J; Su H; Zhu C; Xu Y; Zhang F
Eur Arch Otorhinolaryngol; 2024 Feb; 281(2):547-561. PubMed ID: 37801162
[TBL] [Abstract] [Full Text] [Related]
3. Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study.
Liu M; Xu X; Fan S; Ren H; Zhao Y; Guan H
Neurol Sci; 2024 Jan; 45(1):253-260. PubMed ID: 37580515
[TBL] [Abstract] [Full Text] [Related]
4. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Kademane K; Chai Soon Hou S; Jocelyn TXY; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011272. PubMed ID: 37432030
[TBL] [Abstract] [Full Text] [Related]
5. Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.
Aydin B; Beklen H; Arga KY; Bayrakli F; Turanli B
J Endocrinol Invest; 2023 Apr; 46(4):727-747. PubMed ID: 36306107
[TBL] [Abstract] [Full Text] [Related]
6. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer -Basal cell Carcinoma or Squamous cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study.
Miñano Medrano R; López Estebaranz JL; Sanmartin-Jiménez O; Garcés JR; Rodríguez-Prieto MA; Vilarrasa-Rull E; de Eusebio-Murillo E; Escutia-Muñoz B; Flórez-Menéndez Á; Artola-Igarza JL; Alfaro-Rubio A; Redondo P; Delgado-Jiménez Y; Sánchez-Schmidt JM; Allende-Markixana I; Alonso-Pacheco ML; García-Bracamonte B; de la Cueva-Dobao P; Navarro-Tejedor R; Ciudad-Blanco C; Carnero-González L; Vázquez-Veiga H; Cano-Martínez N; Ruiz-Salas V; Sánchez-Sambucety P; Botella-Estrada R; González-Sixto B; Martorell-Calatayud A; Gil P; Morales-Gordillo V; Toll-Abelló A; Ocerin-Guerra I; Mayor-Arenal M; Suárez-Fernández R; Sainz-Gaspar L; Descalzo MA; García-Doval I;
Actas Dermosifiliogr; 2022 May; 113(5):451-458. PubMed ID: 35431059
[TBL] [Abstract] [Full Text] [Related]
7. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger SM; Buder-Bakhaya K; Lo SN; Forschner A; McKean M; Zimmer L; Khoo C; Dummer R; Eroglu Z; Buchbinder EI; Ascierto PA; Gutzmer R; Rozeman EA; Hoeller C; Johnson DB; Gesierich A; Kölblinger P; Bennannoune N; Cohen JV; Kähler KC; Wilson MA; Cebon J; Atkinson V; Smith JL; Michielin O; Long GV; Hassel JC; Weide B; Haydu LE; Schadendorf D; McArthur G; Ott PA; Blank C; Robert C; Sullivan R; Hauschild A; Carlino MS; Garbe C; Davies MA; Menzies AM
Eur J Cancer; 2022 Feb; 162():22-33. PubMed ID: 34952480
[TBL] [Abstract] [Full Text] [Related]
8. Risk of Developing Melanoma With Systemic Agents Used to Treat Psoriasis: A Review of the Literature.
Semaka A; Salopek TG
J Cutan Med Surg; 2022; 26(1):87-92. PubMed ID: 34392725
[TBL] [Abstract] [Full Text] [Related]
9. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.
Di Guardo L; Randon G; Corti F; Vallacchi V; Raimondi A; Fucà G; Bini M; Maurichi A; Patuzzo R; Gallino G; Mattavelli I; Ruggeri R; Angi M; Cossa M; Valeri B; Cimminiello C; Santinami M; Rivoltini L; de Braud F; Rodolfo M; Vecchio MD
Oncologist; 2021 Dec; 26(12):1079-1084. PubMed ID: 34355463
[TBL] [Abstract] [Full Text] [Related]
10. EIGHTEEN-MONTH RESULTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON VISION AND MICROCIRCULATION IN RADIATION MACULOPATHY.
Eandi CM; Polito MS; Schalenbourg A; Zografos L
Retina; 2021 Sep; 41(9):1883-1891. PubMed ID: 33411473
[TBL] [Abstract] [Full Text] [Related]
11. Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma.
Wilson MA; Zhong J; Johannet P; Lee Y; Masub N; Wechter T; Moran U; Berman RS; Shapiro RL; Weber J; Pavlick A; Osman I
Melanoma Res; 2020 Oct; 30(5):492-499. PubMed ID: 32804707
[TBL] [Abstract] [Full Text] [Related]
12. How well do image-defined risk factors (IDRFs) predict surgical outcomes and survival in patients with neuroblastoma? A systematic review and meta-analysis.
Parhar D; Joharifard S; Lo AC; Schlosser MP; Daodu OO
Pediatr Surg Int; 2020 Aug; 36(8):897-907. PubMed ID: 32533235
[TBL] [Abstract] [Full Text] [Related]
13. Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients.
Wohlmuth C; Wohlmuth-Wieser I; May T; Vicus D; Gien LT; Laframboise S
Am J Clin Dermatol; 2020 Apr; 21(2):285-295. PubMed ID: 31784896
[TBL] [Abstract] [Full Text] [Related]
14. Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma.
Wakeam E; Adibfar A; Stokes S; Leighl NB; Giuliani ME; Varghese TK; Darling GE
J Thorac Cardiovasc Surg; 2020 May; 159(5):2043-2054.e9. PubMed ID: 31759623
[TBL] [Abstract] [Full Text] [Related]
15. The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice.
Alexandraki KI; Pizanias M; Uri I; Thomas D; Page T; Kolomodi D; Low CS; Adesanya O; Tsoli M; Gross DJ; Randeva H; Srirajaskanthan R; Grozinsky-Glasberg S; Kaltsas G; Weickert MO
Endocrine; 2019 Jun; 64(3):690-701. PubMed ID: 30635793
[TBL] [Abstract] [Full Text] [Related]
16. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
[TBL] [Abstract] [Full Text] [Related]
17. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
Franken MG; Leeneman B; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; van der Hoeven KJM; Hospers GAP; Kapiteijn E; Koornstra R; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van Zeijl M; Haanen JBAG; Uyl-de Groot CA
Anticancer Drugs; 2018 Jul; 29(6):579-588. PubMed ID: 29634490
[TBL] [Abstract] [Full Text] [Related]
18. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract] [Full Text] [Related]
19. An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas.
Abdel-Rahman O
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1071-1076. PubMed ID: 28889760
[TBL] [Abstract] [Full Text] [Related]
20. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Iizuka H; Uehara J; Otsuka F; Fujisawa Y; Takenouchi T; Isei T; Iwatsuki K; Uchi H; Ihn H; Minami H; Tahara H
Cancer Sci; 2017 May; 108(5):1022-1031. PubMed ID: 28266140
[TBL] [Abstract] [Full Text] [Related]
[Next]
